Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer

Abstract The androgen receptor inhibitor enzalutamide is one of the principal treatments for metastatic prostate cancer. Most patients respond. However, a subset is primary refractory. Seeking to understand enzalutamide extreme non-response (ENR), we analyzed RNA-sequencing in biopsies from men trea...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	npj Precision Oncology
المؤلفون الرئيسيون:	Anbarasu Kumaraswamy, Ya-Mei Hu, Joel A. Yates, Chao Zhang, Eva Rodansky, Dhruv Khokhani, Diana Flores, Zhi Duan, Yi Zhang, Shaadi Tabatabaei, Rachel Slottke, Shangyuan Ye, Primo Lara, Adam Foye, Charles J. Ryan, David A. Quigley, Jiaoti Huang, Rahul Aggarwal, Robert E. Reiter, Max S. Wicha, Tomasz M. Beer, Matthew Rettig, Martin Gleave, Christopher P. Evans, Owen N. Witte, Joshua M. Stuart, George V. Thomas, Felix Y. Feng, Eric J. Small, Zheng Xia, Joshi J. Alumkal
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Nature Portfolio 2025-07-01
الوصول للمادة أونلاين:	https://doi.org/10.1038/s41698-025-01002-8